Description: Design Therapeutics, Inc. develops therapies for the treatment of degenerative disorders caused by nucleotide repeat expansions. The company engages in the development of a program for the treatment of Friedreich's ataxia and degenerative diseases such as Fragile X syndrome and myotonic dystrophy. The company was incorporated in 2017 and is based in Carlsbad, California.
Home Page: www.designtx.com
DSGN Technical Analysis
6005 Hidden Valley Road
Carlsbad,
CA
92011
United States
Phone:
858 293 4900
Officers
| Name | Title |
|---|---|
| Dr. João Siffert M.D. | Pres, CEO & Director |
| Dr. Sean Jeffries Ph.D. | Chief Operating Officer |
| Dr. Aseem Z. Ansari Ph.D. | Co-Founder & Scientific Advisor |
| Ms. Julie D. Burgess CPA | Chief Accounting Officer |
| Dr. Elizabeth Gordon Ph.D. | Sr. VP of Regulatory Affairs |
| Dr. Jae B. Kim FACC, M.D. | Chief Medical Officer |
| Ms. Dawn Giangiulio | Controller |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.289 |
| Price-to-Sales TTM: | 22642.0122 |
| IPO Date: | 2021-03-26 |
| Fiscal Year End: | December |
| Full Time Employees: | 56 |